[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519988":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":22,"locations":28,"responsibleParty":103,"collaborators":105,"id":108,"slug":7,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":7,"enrollmentInfo":116,"targetDuration":7,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":7,"overallStatus":74,"whyStopped":7,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",null,[9,13,16,19],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Radiotherapy - Low risk group","20 fractions completed in 4 weeks",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Radiotherapy - Standard risk group","25 fractions completed in 5 weeks",{"type":10,"name":17,"description":18,"armGroupLabels":7,"otherNames":7},"Radiotherapy - Intermediate risk group","30 fractions completed in 6 weeks",{"type":10,"name":20,"description":21,"armGroupLabels":7,"otherNames":7},"Radiotherapy - High risk group","35 fractions completed in 7 weeks",[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Ali Hosni","CONTACT","416-946-2360","ali.hosni@uhn.ca",[29,45,58,72,88],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Allegheny Health Network","NOT_YET_RECRUITING","Pittsburgh","Pennsylvania","15212","United States",{"type":37,"coordinates":38},"Point",[39,40],-79.99589,40.44062,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":7,"phoneExt":7,"email":7},"Alexander Kirichenko, MD",{"facility":46,"status":31,"city":47,"state":48,"zip":49,"country":35,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Medical College of Wisconsin Cancer Center","Milwaukee","Wisconsin","53226",{"type":37,"coordinates":51},[52,53],-87.90647,43.0389,{"lat":53,"lon":52},[56],{"name":57,"role":25,"phone":7,"phoneExt":7,"email":7},"William A Hall, MD",{"facility":59,"status":31,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Austin Health","Heidelberg","Victoria","3084","Australia",{"type":37,"coordinates":65},[66,67],145.06667,-37.75,{"lat":67,"lon":66},[70],{"name":71,"role":25,"phone":7,"phoneExt":7,"email":7},"Ee Siang Choong, MD",{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2C1","Canada",{"type":37,"coordinates":80},[81,82],-79.39864,43.70643,{"lat":82,"lon":81},[85],{"name":86,"role":25,"phone":26,"phoneExt":7,"email":87},"Ali Hosni, MD","ali.hosni.abdalaty@rmp.uhn.ca",{"facility":89,"status":31,"city":90,"state":91,"zip":92,"country":78,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"CHUM - Centre hospitalier de l'Université de Montréal","Montreal","Quebec","H2X 0C1",{"type":37,"coordinates":94},[95,96],-73.58781,45.50884,{"lat":96,"lon":95},[99],{"name":100,"role":25,"phone":101,"phoneExt":7,"email":102},"Mame Daro Faye, MD","514 890-8254","mame.daro.faye.med@ssss.gouv.qc.ca",{"type":104,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[106],{"name":107,"class":6},"Medical College of Wisconsin","100519988",false,"NCT06050707","MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach","MAESTRO","Inclusion Criteria:\n\n* Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible.\n* Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) \u002F the American Joint Committee on Cancer (AJCC) 8th Ed)\n* Patients must be eligible for definitive RT or CRT\n* Must be ≥ 18 years of age\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer.\n* Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.\n* Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.","ALL","18 Years",{"count":117,"type":118},80,"ESTIMATED","INTERVENTIONAL",[121],"PHASE2","The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.",[124],"Anal Squamous Cell Carcinoma","2026-06-09",{"date":127,"type":128},"2026-06-10","ACTUAL",{"date":130,"type":128},"2023-09-29",{"date":132,"type":118},"2028-09-01",{"name":5,"class":6},5]